Stock Analysis

Careium Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

OM:CARE
Source: Shutterstock

Careium (STO:CARE) Third Quarter 2024 Results

Key Financial Results

  • Revenue: kr201.7m (down 7.2% from 3Q 2023).
  • Net income: kr10.0m (down 12% from 3Q 2023).
  • Profit margin: 5.0% (down from 5.2% in 3Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: kr0.41 (down from kr0.47 in 3Q 2023).
earnings-and-revenue-growth
OM:CARE Earnings and Revenue Growth October 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Careium EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 37%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Careium is showing 1 warning sign in our investment analysis that you should know about...

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.